Sichuan Kelun-Biotech Biopharmaceutical

Kelun-Biotech Secures New Drug Approval for SKB118: Investor and BD Guide

FDA · oncology · 5 min

Kelun-Biotech has secured Investigational New Drug (IND) approval from China's CDE for its novel PD-1 x VEGF bispecific antibody, SKB118. This milestone opens the door for clinical development and presents significant opportunities and competitive considerations for the pharmaceutical industry.

Merck's TroFuse-005 Trial Results: Implications for Investors and Pharma Teams

advanced or recurrent endometrial cancer · 3 min

Merck's TroFuse-005 trial evaluating Sacituzumab Tirumotecan has met primary endpoints of overall survival and progression-free survival in advanced endometrial cancer. This article explores the implications for investors and pharmaceutical teams.

Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss

3 min

This article delves into Merck-Kelun ADC's recent achievements in China and the implications of Takeda's significant antitrust loss, providing strategic insights for business development teams and investors.

Merck-Kelun Lung Cancer Drug Cuts Tumor Progression Risk by 65%

lung cancer · 2 min

Merck-Kelun's recent trial results indicate a significant breakthrough in lung cancer treatment, with a 65% reduction in tumor progression risk. This article explores the implications for the pharmaceutical industry.

#ASCO26: Kelun's Phase 3 Lung Cancer Success with Merck

lung cancer · 3 min

Kelun's Phase 3 study on lung cancer in partnership with Merck showcased significant success at ASCO26. This article explores the implications for the pharma industry.

Merck’s Billion-Dollar Bet on TROP2: Regulatory Updates and Implications

endometrial cancer · 4 min

Merck's strategic investment in Kelun-Biotech's TROP2 shows promising survival benefits in endometrial cancer. This analysis covers the regulatory updates and their implications for investors.